¡Ya estamos en ! Descubre más

Alnylam Pharmaceuticals

ALNY

Capitalización de mercado USD 31 mil M

231.83 USD

-2.20

0.94%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

231.83

0.00

0%

1 día

-0.94%

5 días

-0.56%

1 mes

-3.15%

3 meses

-18.12%

6 meses

-27.58%

En lo que va del año

-42.07%

1 año

-51.81%

5 años

13.7%

10 años

533.76%

Acerca de: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Empleados: 2,500

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 15.3%

Neutral 72.9%

Negativo 11.9%

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026 at 8:30 am ET. A live audio w.

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

The Motley Fool

Alnylam vs. Ionis: Here's the Better Bad-News Buy

Alnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra. Ionis experienced two pipeline setbacks on the same day in July.

Alnylam vs. Ionis: Here's the Better Bad-News Buy

CNBC Television

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of the federal securities laws.

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company's possible violations of federal securities laws.

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,' a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play' aims to help people recognize the symptoms of ATTR-CM earlie.

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

Alnylam Pharmaceuticals, Inc. shares have fallen 18% amid concerns over its ATTR-CM franchise following AstraZeneca/Ionis trial failure. I see pessimism as understandable but overdone; nucresiran's superior TTR knockdown and trial design differences support a credible case for TRITON-CM success. Even if TRITON-CM fails, Amvuttra's first-line share gains and Alnylam's diverse pipeline mitigate downside risk.

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

Zacks Investment Research

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

The Motley Fool

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

Wall Street analysts are overwhelmingly bullish about Alnylam. The stock's attractive valuation and the company's growth prospects appear to support their enthusiasm.

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™